期刊档案 · Medicine-Oncology
Cancer Biology & Medicine
ISSN 2095-3941 · Chinese Anticancer Association · China · Quarterly · 创刊 2012
Cancer Biology & Medicine 中科院 医学 2区（2025 年升级版），影响因子 13.92，完全开放获取，APC 约 2,800 美元，投稿社区反馈审稿约 12 周，2025 年发文 120 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Cancer Biology & Medicine 由 Chinese Anticancer Association 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Cancer Genomics and Diagnostics 等主题的论文，这 3 个主题约占 22.7%，主导子领域为 Oncology、Cancer Research。（根据 OpenAlex 主题统计与中科院分区数据生成）
Cancer Biology & Medicine is dedicated to reporting latest advances in cancer research around the world by presenting high quality articles, especially on translational cancer research, to bridge the gap between bench and beside. Meanwhile, the journal promotes academic exchange in cancer area between China and the rest of the world to keep cancer researchers and clinicians updated with current knowledge of novel findings and recent advances in oncology. The scope covers the following topics:
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Oncology
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Cancer Immunotherapy and BiomarkersMedicine12.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.3%
- Lung Cancer Treatments and MutationsMedicine5%
- Ferroptosis and cancer prognosisMedicine5%
- Immune cells in cancerImmunology and Microbiology4.7%
- Cancer Cells and MetastasisMedicine4.5%
- CAR-T cell therapy researchMedicine4.4%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 医学：研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 2 区 |
| 小类 | 肿瘤学ONCOLOGY | 2 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 1 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 1 区 |
| 小类 | 肿瘤学ONCOLOGY | 2 区 |
| 小类 | 医学：研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 2 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 医学：研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
MEDLINEPMCEmbaseCAS出版商官网
其他：BIOSIS Previews、EBSCO
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 13.92LetPub ·
- CiteScore 2026-06
- 11.5LetPub ·
- SJR 2026-06
- 1.89LetPub ·
- SNIP 2026-06
- 1.37LetPub ·
- h-index
- 29LetPub ·
- h-index
- 71OpenAlex ·
- i10-index
- 490OpenAlex ·
- 两年平均被引
- 5.27OpenAlex ·
- 自引率
- 0.8%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 68LetPub ·
逐年发文量 OpenAlex 统计 · 累计 967 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 111 | 111 | 58 |
| 2025 | 120 | 120 | 524 |
| 2024 | 85 | 85 | 1,083 |
| 2023 | 95 | 95 | 1,549 |
| 2022 | 60 | 60 | 1,606 |
| 2021 | 154 | 154 | 4,044 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 12 WeeksLetPub ·
- 投稿到首次决定
- 7 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 12 周DOAJ ·
- 评审方式
- 同行评审（未说明方式）DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,800 / JPY 19,000 | 无 | CC BY-NC | |
| OpenAlex | USD 1,500 | — | — |
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点4 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- ≤ 5 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 投稿信（Cover letter）
- 必须提供
接收的文章类型8 种
- editorialEditorials are comprised of commentary and analysis on the leading-edge discoveries in cancer research and significant advances in cancer diagnosis and treatmen…未说明篇幅
- letterLetters include significant and focused findings of original studies with characteristics of concise, novelty, and timely.Abstract or the structure of original …未说明篇幅
- letter to the editorReaders are encouraged to comment on articles published in Cancer Biology & Medicine, via Letters to the Editor. Letters to the editor will not undergo peer rev…未说明篇幅
- minireviewOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.未说明篇幅
- original articleOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.未说明篇幅
- perspectiveOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.未说明篇幅
- practice guidelineOriginal Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, and Practice Guideline.未说明篇幅
- reviewReviews discuss recent progress on topics of broad interest to cancer researchers or cancer care professionals. Solicited reviews will also be sent out for peer…未说明篇幅
官网政策摘录作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、自存档
- 作者资格 Authorship and Contributorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. The manuscript’s content and its submission for publication should be approved by all authors who should sig…
原文 ↗出版商官网 ·- 利益冲突 Conflict of Interest
Conflict of interest disclosure required for all authors. 模型摘要
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology & Medicine requires all authors to disclose any relationship that might result in an actual, potential, or perceived conflict of interest about the manuscript submitted for review. Reviewe…
原文 ↗出版商官网 ·- 出版伦理 Checking for Scientific Misconduct
Cancer Biology & Medicine has an obligation to ensure that its published articles are accurate and adheres to the highest ethical standard. Editors check all submissions using CrossCheck. In the cases of plagiarism, redundant or duplicate publication, the journal will send a letter of reprimand to the authors’ institution, publish a notice of misconduct and formally retract the published manuscrip…
原文 ↗出版商官网 ·- 许可与版权 Copyright and Permissions
If a manuscript includes copyrighted materials of others, authors must obtain written permission from the copyright owners and indicate the sources in the article. The written permission should be simultaneously submitted with the manuscript.
原文 ↗出版商官网 ·- 开放获取 Open Access
Open access. 模型摘要
All articles published in Cancer Biology & Medicine are made freely and permanently available online immediately upon publication, without subscription charges or registration barriers.
原文 ↗出版商官网 ·- 同行评审 Peer Review
After initial review by the editor or sometimes by an editorial board member, manuscripts without sufficient priority for publication will be editorially rejected within 7 days. Those qualifying for peer review will be sent to at least two expert reviewers for unbiased, independent and critical assessment. Reviewers are asked to provide an overall recommendation supported by detailed comments on t…
原文 ↗出版商官网 ·- 自存档 Embargo Policy
Scientific information in a manuscript which is under consideration or in press in Cancer Biology & Medicine may not be discussed with the media before publication. Preliminary reporting to public media, governmental agencies, or manufacturers should not jeopardize publication, and should be discussed with and approved by the editor in advance.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Chinese Anticancer Association
- 出版国家或地区
- China
- 出版语言
- English
- 出版周期
- Quarterly
- 创刊年份
- 2012
- ISSN
- 2095-3941
- 官网最新一期
- Volume 23, Issue 8（2026 年 8 月）
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
常见问题
关于 Cancer Biology & Medicine 的常见问题
Cancer Biology & Medicine 是中科院几区期刊？
2025 年升级版分区表中，Cancer Biology & Medicine 为医学 2区，小类 医学：研究与实验 / 肿瘤学 2 区。2026 年新锐版分区表中为医学 1区。不同版本与大小类分区不能混用。
Cancer Biology & Medicine 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 13.92，CiteScore 为 11.5，h-index 为 71。
Cancer Biology & Medicine 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 12 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Cancer Biology & Medicine 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：≤ 5 个；参考文献格式：顺序编码制（按引用顺序编号）；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Cancer Biology & Medicine 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Cancer Biology & Medicine 被 SCIE、Scopus、DOAJ 收录。期刊官网自述还被 MEDLINE、PMC、Embase、CAS 收录，该清单未与各数据库逐一核对。
Cancer Biology & Medicine 是开放获取期刊吗？版面费多少？
Cancer Biology & Medicine 为完全开放获取。APC 约 2,800 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。